Take the right dataset, add an ingenious algorithm or two – and voilá! Your billion-euro blockbuster molecule is ready! AI-driven drug development is exciting investor interest, while Big Pharma is also asking what forms of artifical intelligence can be slotted in at what stages in the process. AI-powered drug repurposing has seen some candidates enter clinical stage testing, but it’s still unclear whether the technology is already powerful enough for de novo molecule discovery.
Ose Pharma gets clinical milestone for IL7R antagonist
Latest NewsOse Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016.
How stroma cells trigger tumour angiogenesis
Latest NewsAnalyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Kiadis Pharma appoints Dr. Robert Friesen as CSO
AppointmentsKiadis Pharma N.V., a clinical-stage biopharmaceutical company, on Monday announced the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019.
Jennewein Biotechnologie expands into Chinese market
Latest NewsMedicxi put €40m into two Sosei spin off companies
Latest NewsSosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.
EMA greenlights two orphan drugs and two biosimilars
Latest NewsEMA’s human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting.
Hitachi expands European reach in cell and gene therapy
Latest NewsHitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US.
Dewpoint Therapeutics kicks off with $60m financing
Latest NewsDewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
IPO: Marinomed sets offer price
Latest NewsMarinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share.
Can machines learn to discover drugs?
BackgroundTake the right dataset, add an ingenious algorithm or two – and voilá! Your billion-euro blockbuster molecule is ready! AI-driven drug development is exciting investor interest, while Big Pharma is also asking what forms of artifical intelligence can be slotted in at what stages in the process. AI-powered drug repurposing has seen some candidates enter clinical stage testing, but it’s still unclear whether the technology is already powerful enough for de novo molecule discovery.